Sugi Predict

Sugi Predict / Compounds / SCHEMBL1468084

SCHEMBL1468084

SCHEMBL1468084

O=C(O)c1cn(S(=O)(=O)c2ccccc2)c2c(F)cccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.54
▸ AKR1C1 Q04828 1/20 0.54
▸ LMNA P02545 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ TNFSF11 O14788 1/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ PLK1 P53350 1/20 0.47
▸ FABP4 P15090 2/20 0.45
▸ CHRM1 P11229 1/20 0.42
▸ TNF P01375 1/20 0.41
▸ HTR6 P50406 5/20 0.40
▸ ALOX5 P09917 1/20 0.39
▸ PTGS2 P35354 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12748738 0.91 AKR1C3 (0.64) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL12748741 0.86 AKR1C3 (0.47) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL1466938 0.84 AKR1C3 (0.56) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL12748677 0.83 AKR1C3 (0.54) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL1465894 0.83 AKR1C3 (0.54) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL12748662 0.82 AKR1C3 (0.53) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL12748681 0.81 AKR1C3 (0.52) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL12993890 0.80 MEN1 (0.53) AKR1C3AKR1C1LMNASMN1; SMN2MEN1
SCHEMBL12748689 0.80 AKR1C3 (0.51) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11
SCHEMBL2111716 0.80 HTR6 (0.42) AKR1C3AKR1C1LMNASMN1; SMN2TNFSF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101395134-B 17 beta-hydroxysteroid dehydrogenase type 5 inhibitors ASTELLAS PHARMA INC 2011-08-31 — — CN claimed
US-7855225-B2 17βHSD type 5 inhibitor ASTELLAS PHARMA INC. (JP) 2010-12-21 — — US claimed
US-20090181960-A1 Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer ASTELLAS PHARMA INC. (JP) 2009-07-16 — — US claimed
CN-101395134-A 17 beta-hydroxysteroid dehydrogenase type 5 inhibitors ASTELLAS PHARMA INC (JP) 2009-03-25 — — CN claimed
EP-1990335-A1 17 BETA HSD TYPE 5 INHIBITOR Astellas Pharma Inc. (JP) 2008-11-12 — — EP claimed
CN-101395134-B 17 beta-hydroxysteroid dehydrogenase type 5 inhibitors ASTELLAS PHARMA INC 2011-08-31 — — CN disclosed
US-20110071146-A1 17BetaHSD Type 5 Inhibitor ASTELLAS PHARMA INC. 2011-03-24 — — US disclosed
US-20110071146-A1 17BetaHSD Type 5 Inhibitor ASTELLAS PHARMA INC. 2011-03-24 — — US disclosed
US-20110071146-A1 17BetaHSD Type 5 Inhibitor ASTELLAS PHARMA INC. 2011-03-24 — — US disclosed
US-7855225-B2 17βHSD type 5 inhibitor ASTELLAS PHARMA INC. (JP) 2010-12-21 — — US disclosed
US-7855225-B2 17βHSD type 5 inhibitor ASTELLAS PHARMA INC. (JP) 2010-12-21 — — US disclosed
US-20090181960-A1 Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer ASTELLAS PHARMA INC. (JP) 2009-07-16 — — US disclosed
US-20090181960-A1 Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer ASTELLAS PHARMA INC. (JP) 2009-07-16 — — US disclosed
CN-101395134-A 17 beta-hydroxysteroid dehydrogenase type 5 inhibitors ASTELLAS PHARMA INC (JP) 2009-03-25 — — CN disclosed
EP-1990335-A1 17 BETA HSD TYPE 5 INHIBITOR Astellas Pharma Inc. (JP) 2008-11-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071146-A1 17BetaHSD Type 5 Inhibitor CYP17A1, HSD17B3, HSD3B1 AKR1C3 189/4885AKR1C1 291/4885LMNA 475/4885
US-20090181960-A1 Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer CYP17A1, HSD17B3, HSD17B1 AKR1C3 109/4885AKR1C1 134/4885LMNA 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.